Back

Ecraid Expands Role in European Pandemic Preparedness Initiatives

At a glance

  • Lennie Derde appointed CEO of Ecraid effective 1 January 2026
  • Ecraid supports BE READY NOW, a new European pandemic partnership
  • Network includes over 2,000 sites in more than 40 countries

Efforts to strengthen Europe’s response to infectious disease threats have led to the expansion of Ecraid, a clinical research network, and the launch of new collaborative partnerships across the continent.

Ecraid operates as a pan-European, not-for-profit network focused on clinical research for infectious diseases. The organisation was established to enhance Europe’s capacity to address emerging health threats by coordinating research activities and infrastructure.

The network’s development is rooted in earlier EU-funded projects, including COMBACTE and PREPARE. Ecraid was further established through ECRAID-Plan and ECRAID-Base, which received €30 million in EU investment in 2021 to build research capacity.

ECRAID-Base currently includes more than 2,000 clinical research sites located in over 40 European countries. The network supports six ongoing clinical studies, providing a foundation for rapid research mobilisation during health emergencies.

What the numbers show

  • €30 million invested by the EU in 2021 for Ecraid’s development
  • Over 2,000 clinical research sites included in ECRAID-Base
  • 81 organisations from 27 countries participate in BE READY NOW
  • Six perpetual clinical studies supported by Ecraid
  • Official BE READY NOW launch ceremony scheduled for 17 February 2026

Ecraid’s leadership will transition with the appointment of Lennie Derde as Chief Executive Officer, effective 1 January 2026. This change aligns with the organisation’s ongoing efforts to expand its role in European pandemic preparedness.

In addition to its existing activities, Ecraid is a key supporter of the BE READY NOW European Partnership for Pandemic Preparedness. This partnership, launched on 1 January 2026, aims to create a continuously active research ecosystem capable of responding quickly to new health threats.

Within BE READY NOW, Ecraid leads two work packages focused on building interconnected research networks and standardising data protocols for pandemic response. These initiatives are intended to improve coordination and data sharing among participating organisations.

The BE READY NOW consortium includes 81 organisations from 27 countries. A virtual kick-off meeting was held in January 2026, and an official launch ceremony is planned for 17 February 2026 in Paris to mark the beginning of this collaborative effort.

* This article is based on publicly available information at the time of writing.

Related Articles

  1. EC-Council introduced four AI certifications in Paris, aligning with France's national AI strategy and the €700 million France 2030 education plan.

  2. A deep-learning model from Google DeepMind, AlphaGenome, predicts DNA variant effects, launched for non-commercial research via API on June 25, 2025.

  3. Recent approvals for oral Wegovy and pediatric use may affect treatment options for chronic diseases and obesity in adolescents and adults.

  4. New equity-focused hiring practices by the Obama Foundation aim to enhance workforce diversity for the Presidential...

  5. Gynaecology waiting lists in Northern Ireland surpass 50,700, revealing significant strain on the healthcare system.

More on Health

  1. The UN sanctions committee approved 17 humanitarian aid projects for North Korea, allowing food and medical assistance from various groups.

  2. Data from 33 London boroughs and charities is integrated by LOTI, utilizing IoT sensors to enhance housing conditions and service delivery.

  3. A report shows 41% of adolescents saw online ads for prescription weight-loss drugs. The Children's Commissioner calls for a ban on such ads.

  4. Adam Mosseri testified in a California trial on February 11, 2026, addressing social media's impact on youth, according to court documents.

  5. A filing details that Impel Pharmaceuticals sold assets for $17.5 million and concluded its Chapter 11 process, according to court documents.